Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ESPR

ESPR - Esperion Therapeutics Inc Stock Price, Fair Value and News

$3.46+0.04 (+1.17%)
Market Closed

12/100

ESPR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

12/100

ESPR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.51

Target 3M

$2.83

Target 6M

$2.67

ESPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ESPR Price Action

Last 7 days

16.1%

Last 30 days

-11.0%

Last 90 days

21.8%

Trailing 12 Months

77.4%

ESPR RSI Chart

ESPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ESPR Valuation

Market Cap

827.2M

Price/Earnings (Trailing)

-7.82

Price/Sales (Trailing)

2.72

Price/Free Cashflow

-8.87

ESPR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.51

Target 3M

$2.83

Target 6M

$2.67

ESPR Fundamentals

ESPR Revenue

Revenue (TTM)

303.8M

Rev. Growth (Yr)

69.1%

Rev. Growth (Qtr)

5.98%

ESPR Earnings

Earnings (TTM)

-105.8M

Earnings Growth (Yr)

-6.13%

Earnings Growth (Qtr)

-146.23%

ESPR Profitability

Return on Equity

23.45%

Return on Assets

-29.07%

Free Cashflow Yield

-11.28%

ESPR Investor Care

Shares Dilution (1Y)

21.33%

Diluted EPS (TTM)

-0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025259.6M268.1M303.8M0
2024229.7M277.8M295.5M332.3M
202381.0M87.9M102.9M116.3M
202289.3M67.5M72.1M75.5M
2021233.7M62.1M72.7M78.4M
2020168.2M188.0M207.8M227.5M
2019000148.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Esperion Therapeutics Inc

ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
 CEO
 WEBSITEesperion.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES199

Esperion Therapeutics Inc Frequently Asked Questions

ESPR is the stock ticker symbol of Esperion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Esperion Therapeutics Inc is 827.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ESPR's fair value in chart for subscribers.

The fair value guage provides a quick view whether ESPR is over valued or under valued. Whether Esperion Therapeutics Inc is cheap or expensive depends on the assumptions which impact Esperion Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ESPR.

As of Wed Jan 28 2026, ESPR's PE ratio (Price to Earnings) is -7.82 and Price to Sales (PS) ratio is 2.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ESPR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Esperion Therapeutics Inc has provided -0.136 (multiply by 100 for percentage) rate of return.